- Home
- SLNH vs SNY Comparison
SLNH vs SNY Comparison
Compare SLNH & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLNH | SNY |
|---|---|---|
| Founded | 1961 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.8M | 119.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SLNH | SNY |
|---|---|---|
| Price | $1.90 | $48.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $5.00 | ★ $61.50 |
| AVG Volume (30 Days) | ★ 5.0M | 2.6M |
| Earning Date | 11-17-2025 | 01-29-2026 |
| Dividend Yield | N/A | ★ 3.28% |
| EPS Growth | N/A | ★ 105.93 |
| EPS | N/A | ★ 8.67 |
| Revenue | $28,782,000.00 | ★ $53,890,648,839.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | $42.68 | $6.47 |
| P/E Ratio | ★ N/A | $11.13 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.36 | $44.62 |
| 52 Week High | $5.14 | $60.12 |
Technical Indicators
Market Signals| Indicator | SLNH | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 47.49 | 43.35 |
| Support Level | $1.78 | $47.80 |
| Resistance Level | $1.91 | $49.24 |
| Average True Range (ATR) | 0.24 | 0.64 |
| MACD | 0.07 | -0.16 |
| Stochastic Oscillator | 51.76 | 29.77 |
Price Performance
Historical ComparisonAbout SLNH Soluna Holdings Inc.
Soluna Holdings Inc is a U.S.-based company that conducts operations through its subsidiary. The group is engaged in the mining of cryptocurrency through data centers that can be powered by renewable energy sources. The data centers buy every excess megawatt to use for batch-oriented, computing-intensive processes such as cryptocurrency mining or machine learning which is a low-risk and low-friction solution to use as a smartphone.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.